A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
Titel:
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
Auteur:
Yoshioka, H. Azuma, K. Yamamoto, N. Takahashi, T. Nishio, M. Katakami, N. Ahn, M.J. Hirashima, T. Maemondo, M. Kim, S.W. Kurosaki, M. Akinaga, S. Park, K. Tsai, C.M. Tamura, T. Mitsudomi, T. Nakagawa, K.